Diabetes, incretin hormones and cardioprotection

Heart

Volumn 100, Issue 19, 2014, Pages 1550-1561

  Myat, A ^a   Redwood, S R ^a   Gersh, B J ^b   Yellon, D M ^c   Marber, M S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b MAYO CLINIC   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; ANTIDIABETIC AGENT; CARDIOTONIC AGENT; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE BLOOD LEVEL;

ARTICLE; AUGMENTATION INDEX; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG SAFETY; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HORMONE ACTION; HUMAN; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PANDEMIC; PROTEIN SECRETION; RETINA ISCHEMIA; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; ANIMAL MODEL; COMPLICATION; DELAYED DIAGNOSIS; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; HEALTH; HEART DISEASES; METABOLISM; PHASE 2 CLINICAL TRIAL (TOPIC);

ANIMALS; BLOOD GLUCOSE; CARDIOTONIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DELAYED DIAGNOSIS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLOBAL HEALTH; GLUCAGON-LIKE PEPTIDE 1; HEART DISEASES; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MODELS, ANIMAL; RECEPTORS, GLUCAGON;

EID: 84907021013     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-303242     Document Type: Article

References (20)

1. Dupre J, Ross S, Watson D, et al. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973;37:826-8.
2. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705. A wonderfully thorough introduction to the incretin hormone arena by two of the world' s key opinion leaders on the topic.
3. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-39. An extremely detailed and comprehensive synopsis of GLP-1 physiology.
4. Nauck MA, Bartels E, Orskov C, et al . Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993;76:912-17. Landmark study demonstrating the additive insulinotropic action of the two predominant incretin hormones.
5. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44:1126-31.
6. Nauck M, Stöckmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;2:46-52. Landmark study defining the reduced incretin effect in type 2 diabetes mellitus.
7. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301-7. Pioneering work on the defective incretin effect in type 2 diabetes.
8. Eng J, Kleinman WA, Singh G, et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem 1992;267:7402-5.
9. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151:1473-86.
10. Singh S, Chang H-Y, Richards TM, et al. Glucagon-like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013;173:534-9.
11. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-6.
12. Astrup A, Rössner S, Van Gaal L, et al . Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-16. An important study demonstrating the safety of liraglutide in a non-diabetic population and its effect on promoting weight loss.
13. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012;33:187-215. An informative and comprehensive review focusing on the effects of incretin hormones beyond glycaemic control.
14. Eurich DT, Simpson S, Senthilselvan A, et al. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ 2013;346:f2267.
15. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008;117:2340-50. Important work highlighting the prospect of GLP-1R independent cardioprotective pathways and the bioactivity of the metabolite GLP 1(9-36).
16. Noyan-Ashraf MH, Shikatani EA, Schuiki I, et al. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation 2013;127:74-85.
17. Gros R, You X, Baggio L, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003;144:2242-52. Important work demonstrating the cardiac abnormalities that arise in knockout mice lacking the GLP-1 receptor.
18. Lønborg J, Kelbæk H, Vejlstrup N, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv 2012;5:288-95.
19. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26.
20. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35. SAVOR-TIMI 53 and EXAMINE are the first two studies to report in a long line of large cardiovascular outcomes trials investigating the safety of incretin based therapies.